【摘要】 目的:观察ERCC1、SLC7A11在食管鳞癌组织中的表达水平,探讨其与食管鳞癌患者新辅助化疗疗效的相关性。方法:采用免疫组化(SP)法检测92例食管鳞癌组织(实验组)和36例食管正常黏膜组织(对照组)中ERCC1和SLC7A11的表达量,并分析其与食管鳞癌患者临床病理特征的关系。结果:食管鳞癌组ERCC1、SLC7A11表达阳性率高于对照组,有统计学差异(P <0.01)。ERCC1高表达与食管鳞癌的临床分期、分化程度及有无淋巴结转移有关(P <0.05),与性别、年龄无关(P>0.05)。SLC7A11高表达与食管鳞癌的临床分期、有无淋巴结转移、及分化程度有关(P <0.05),与性别、年龄无关(P>0.05)。Pearson相关分析显示,ERCC1表达水平与SLC7A11表达水平呈正相关。Kaplan-Meier分析显示ERCC1(+)/SLC7A11(+)高表达的食管鳞癌患者治疗后3年复发率高于阴性表达患者,差异有统计学意义(P<0.05),3年总生存率均低于阴性表达患者(P<0.05)。81例接受新辅助化疗患者中,敏感组59例,耐药组22例,ERCC1在敏感组高表达,与对照组比较差异有显著性(P<0.01); SLC7A11在敏感组高表达,两组中表达差异显著(P<0.05)。结论:ERCC1(+)/SLC7A11(+)高表达的食管鳞癌患者预后较差。因此,ERCC1、SLC7A11有可能作为食管鳞癌患者术前新辅助化疗的预后评估指标。更多还原

【Abstract】 Objective: To observe the changes of ERCC1 and SLC7 A11 expression in esophageal cancer tissue,and to explore the role of ERCC1 and SLC7 A11 in esophageal cancer chemotherapy.Methods: The expression levels of ERCC1 and SLC7 A11 in 92 cases of esophageal cancer tissue( experimental group) and 36 cases of normal esophageal mucosa tissue( control group) were detected by SP immunohistochemical method,and the relationship between the relative transcript levels and clinicopathological characteristics of patients with esophageal cancer was analyzed.Results: The positive rates of ERCC1 and SLC7 A11 expression in esophageal cancer group were higher than those in control group( P <0.01). The high expression of ERCC1 was correlated with the clinical stages,differentiation degrees and lymph node metastasis of esophageal cancer( P < 0.05),but not with gender and age( P >0.05).The high expression of SLC7 A11 was correlated with the clinical stages,lymph node metastasis,and differentiation degrees of esophageal cancer( P <0.05),but not with gender and age( P >0.05).Pearson correlation analysis showed that ERCC1 expression level was positively correlated with SLC7 A11 expression level. Kaplan-Meier analysis showed that the recurrence rate of esophageal cancer patients with ERCC1( +)/SLC7 A11( +) high expression was also higher than that of patients with negative ERCC1/SLC7 A11 expression at 3 years after treatment. The difference was statistically significant( P <0.05).The overall survival rate at 3 years was lower than that of patients with negative expression( P < 0.05).Among81 patients receiving neoadjuvant chemotherapy,there were 59 patients in the sensitive group and 22 patients in the drug resistant group. The positive expression rate of ERCC1 was significantly different between the two groups( P <0.01). The positive expression rate of SLC7 A11 was significantly different between the two groups( P<0.05).Conclusion: The expression levels of ERCC1 and SLC7 A1,to some extent,are of a certain guiding effect on preoperative neoadjuvant chemotherapy in patients with esophageal cancer,and the efficacy of neoadjuvant chemotherapy in patients with ERCC1( +)/SLC7 A11( +) high expression is poor.更多还原